Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GNT

Gentium Spa (GNT)

Gentium Spa Ads
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:GNT
DateTimeSourceHeadlineSymbolCompany
05/16/20068:00AMBusiness WireGentium Begins Trading on NASDAQ; New Ticker Symbol: GENTAMEX:GNTGentium Spa Ads
05/05/20068:42AMBusiness WireGentium to Trade on NASDAQ National MarketAMEX:GNTGentium Spa Ads
04/13/20066:00AMBusiness WireGentium Reports 2005 Financial Results; Provides Financial and Clinical UpdateAMEX:GNTGentium Spa Ads
03/28/20068:00AMBusiness WireGentium Receives First IRB Approval to Begin U.S. Phase III Trial with Defibrotide to Treat Veno-Occlusive Disease with MultiplAMEX:GNTGentium Spa Ads
02/02/20068:00AMBusiness WireGentium to Present at Angiogenesis in Cancer and Vascular Disease Congress; Defibrotide Has Anti-Angiogenic Properties In VitroAMEX:GNTGentium Spa Ads
01/30/20068:00AMBusiness WireGentium's Defibrotide Subject of Independent Study in Japan; First Japanese Study Reports That Defibrotide Shows Success TreatinAMEX:GNTGentium Spa Ads
01/20/20067:30AMBusiness WireGentium Initiates Phase II/III Pediatric Trial with Defibrotide to Prevent Veno-Occlusive Disease; European Group for Blood andAMEX:GNTGentium Spa Ads
11/15/20057:00AMBusiness WireGentium Reports Third Quarter Financial Results; Provides Financial and Clinical UpdateAMEX:GNTGentium Spa Ads
11/07/200510:12AMBusiness WireGentium to Present at Rodman & Renshaw Techvest Seventh Annual Healthcare ConferenceAMEX:GNTGentium Spa Ads
10/17/20056:00AMBusiness WireGentium Completes $10.9 Million Private PlacementAMEX:GNTGentium Spa Ads
10/04/20059:23AMBusiness WireGentium Raises $10.9 Million in Private Offering; Funding to Support New Trials and Continued Development of PipelineAMEX:GNTGentium Spa Ads
09/21/20056:00AMBusiness WireGentium S.p.A. Announces Initiation of Independent Phase I/II Study of Defibrotide to treat Multiple MyelomaAMEX:GNTGentium Spa Ads
09/15/20054:00AMBusiness WireRenowned Bone Marrow Transplantation Expert Richard E. Champlin, M.D., Joins Gentium's Scientific Advisory BoardAMEX:GNTGentium Spa Ads
09/07/20054:00AMBusiness WireGentium S.p.A. Announces Intention to Commence Phase III Trial Following Discussions with FDAAMEX:GNTGentium Spa Ads
08/10/20054:00AMBusiness WireGentium Reports Second Quarter Financial Results, Provides Clinical UpdateAMEX:GNTGentium Spa Ads
08/09/20054:00AMBusiness WireGentium Presented Laboratory Data at XXth Congress of International Society for Thrombosis and Haemostasis; Laboratory Data PresAMEX:GNTGentium Spa Ads
07/13/20054:05PMBusiness WireGentium S.p.A. Announces FDA Agrees Company's CMC Submission is Adequate for Commencing Phase III Clinical Trials with DefibrotiAMEX:GNTGentium Spa Ads
06/16/20056:10PMPR Newswire (US)American Stock Exchange Lists American Depository Shares Representing Ordinary Shares Of Gentium S.p.ANYSE:GNT
06/16/200512:38PMPR Newswire (US)Gentium S.p.A. Announces Pricing of Initial Public OfferingNYSE:GNT
 Showing the most relevant articles for your search:AMEX:GNT